TUG-469 is primarily used in research settings as a selective antagonist for the GPR55 receptor, making it a valuable tool compound in studying endocannabinoid signaling pathways. It has been applied in pharmacological studies to investigate the role of GPR55 in pain modulation, inflammation, and cancer cell proliferation. Due to its ability to block GPR55-mediated effects, TUG-469 helps researchers differentiate GPR55 activity from other cannabinoid receptors like CB1 and CB2. It is also utilized in metabolic and neurological research to explore receptor involvement in conditions such as diabetes, osteoporosis, and neurodegenerative diseases. Its selectivity and potency make it suitable for in vitro and in vivo experiments aimed at validating GPR55 as a therapeutic target.